Vima LLC’s Aurinia Pharmaceuticals AUPH Stock Holding History

Vima LLC’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-25	Closed	-$225	–	452
2023 Q4	$225	Buy	+25	New	+$206	﹤0.01%	387

Other funds holding AUPH

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vima LLC's AUPH Position: Q1 2024 in Review

Vima LLC sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2024, closing a stake of 25 shares — an estimated $225 sold.

Vima LLC first reported a position in AUPH in Q4 2023 and held it in 1 quarter. The position peaked at $225 in Q4 2023. 179 funds tracked by Wall St. Rank hold AUPH as of Q1 2024.

Vima LLC reported no remaining Aurinia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Vima LLC sold 25 Aurinia Pharmaceuticals shares in Q1 2024, an estimated $225.
Vima LLC first reported a position in Aurinia Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Vima LLC's Aurinia Pharmaceuticals position peaked at $225 in Q4 2023.
179 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2024.

Based on Vima LLC's 13F filing for Q1 2024, filed 17 May 2024.